Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 8/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443478 | 0.96 | KCNN4 (0.51) | KCNN4KCNE1KCNQ1MLNRNR1I2 | |
| SCHEMBL2391883 | 0.88 | KCNN4 (0.46) | KCNN4KCNE1KCNQ1MLNRNR1I2 | |
| Dimethylamine SCHEMBL2394420 | 0.81 | KCNN4 (0.41) | KCNN4KCNE1KCNQ1MLNRNR1I2 | |
| SCHEMBL2394417 | 0.81 | KCNH2 (0.41) | KCNN4KCNH2L3MBTL1 | |
| SCHEMBL2392348 | 0.79 | KCNN4 (0.47) | KCNN4KCNE1KCNQ1MLNRNR1I2 | |
| SCHEMBL1443801 | 0.79 | KCNN4 (0.47) | KCNN4KCNE1KCNQ1MLNRNR1I2 | |
| SCHEMBL1508072 | 0.78 | KCNN4 (0.43) | KCNN4KCNE1KCNQ1MLNRNR1I2 | |
| SCHEMBL1507926 | 0.75 | KCNN4 (0.41) | KCNN4KCNE1KCNQ1MLNRNR1I2 | |
| SCHEMBL1507842 | 0.74 | KCNN4 (0.41) | KCNN4KCNE1KCNQ1MLNRNR1I2 | |
| SCHEMBL1508045 | 0.74 | KCNN4 (0.40) | KCNN4KCNE1KCNQ1MLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011034860-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100056637-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090036538-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1968563-A2 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | Icagen, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1158971-B1 | GARDOS CHANNEL ANTAGONISTS | ICAGEN INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | ICAGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007075849-A2 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1158971-A4 | GARDOS CHANNEL ANTAGONISTS | ICAGEN INC (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1158971-A1 | GARDOS CHANNEL ANTAGONISTS | Icagen, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6288122-B1 | A TRIPHENYL ACETAMIDE | ICAGEN, INC. | 2001-09-11 | — | — | US | disclosed |
| WO-2000050026-A1 | GARDOS CHANNEL ANTAGONISTS | ICAGEN, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | KCNH3, KCNH2, KCNJ2 | KCNN4 37/4885KCNE1 20/4885KCNQ1 23/4885 |
| US-20090036538-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | KCNH3, KCNH2, KCNJ2 | KCNN4 37/4885KCNE1 20/4885KCNQ1 23/4885 |
| US-20100056637-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | LTC4S, LTB4R2, CYSLTR2 | KCNN4 2132/4885KCNE1 2203/4885KCNQ1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.